News

Public · Published

Jefferies maintains Hims & Hers Health at Hold, lowers price target to $24 from $31

Jefferies kept its Hold rating on Hims & Hers Health but cut its price target to $24 from $31, a 22.6% reduction. The new target implies 19.3% upside from the November 10 closing price of $20.11. Three other recent analyst targets ranged from $25 to $32.

Published:

Updated:

What happened

Jefferies kept its Hold rating on Hims & Hers Health but cut its price target to $24 from $31, a 22.6% reduction. The new target implies 19.3% upside from the November 10 closing price of $20.11. Three other recent analyst targets ranged from $25 to $32.

Confirmed

Global impact / market context

The lower target signals Jefferies sees less potential value in the shares than before, even while retaining Hold. If other analysts also reduce their targets, investors could become less willing to buy, potentially affecting the company’s share price and its ability to raise funds through stock issuance.

Analyst inference

The three other recent analyst targets cited were all above Jefferies’ new $24 target, ranging from $25 to $32, while their ratings included Equal-Weight, In-Line, and Buy. This small comparison shows differing analyst views, not a confirmed change in Hims & Hers Health’s business performance.

Confirmed

What to watch

  1. Check whether Jefferies provides further explanation for the cut; the supplied report gives the new target and rating but does not state the reason for the lower valuation. Analyst inference
  2. Compare future analyst targets and ratings with the cited $25–$32 range to see whether opinions converge toward Jefferies’ lower $24 target or remain higher. Analyst inference
  3. Look for company updates on sales, costs, and cash available, since changes in those business measures could help explain future analyst assessments of the shares. Analyst inference

Evidence

  • Original source link unavailable